Covered recipient · General Payments record
DONALD L MCNEIL
Allopathic & Osteopathic Physicians Allergy & Immunology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2022 · Entire year
$43,989.09
105 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2022 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $30,800.00 | 7 |
| Travel and Lodging | $6,711.89 | 16 |
| Honoraria | $3,500.00 | 1 |
| Food and Beverage | $2,894.53 | 79 |
| Education | $82.67 | 2 |
By paying entity
PY2022 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| BioCryst US Sales Co., LLC | $37,142.48 | 28 |
| Pharming Healthcare, Inc. | $4,364.81 | 18 |
| AstraZeneca Pharmaceuticals LP | $938.57 | 19 |
| Amgen Inc. | $497.64 | 8 |
| ADMA BioManufacturing LLC | $264.17 | 8 |
| Grifols USA, LLC | $181.30 | 3 |
| Octapharma USA, Inc. | $141.53 | 4 |
| SANOFI-AVENTIS U.S. LLC | $74.99 | 1 |
| GENZYME CORPORATION | $72.79 | 4 |
| Novartis Pharmaceuticals Corporation | $71.95 | 1 |
| Regeneron Healthcare Solutions, Inc. | $71.78 | 4 |
| Blueprint Medicines Corporation | $58.20 | 2 |
| PFIZER INC. | $50.79 | 2 |
| Takeda Pharmaceuticals U.S.A., Inc. | $36.68 | 2 |
| CSL Behring | $21.41 | 1 |
Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
DONALD L MCNEIL
NPI 1134199300 · CMS profile ID 452612
Allopathic & Osteopathic Physicians / Allergy & Immunology
COLUMBUS, OH
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1134199300?year=2022&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- DONALD L MCNEIL, NPI 1134199300, CMS profile ID 452612. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1134199300?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- APA 7
- IndustryPayments. (2026). DONALD L MCNEIL, NPI 1134199300, CMS profile ID 452612. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1134199300?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- Bluebook
- DONALD L MCNEIL, NPI 1134199300, CMS profile ID 452612, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–105 of 105 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1134199300?year=2022&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30
105 matching records · $43,989.09 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–105 of 105.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Octapharma USA, Inc. | $96.29 | 01/18/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 937555481 | CMS |
| Pharming Healthcare, Inc. | $15.68 | 01/14/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 907877893 | CMS |
| AstraZeneca Pharmaceuticals LP | $16.16 | 01/12/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 914658361 | CMS |
| Regeneron Healthcare Solutions, Inc. | $16.95 | 01/05/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 927281121 | CMS |
| ADMA BioManufacturing LLC | $13.84 | 01/01/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 933558305 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $327,822.12 | 97 |
| PY2024 | Recipient | $2,249.76 | 9 |
| PY2024 | Principal investigator | $471,934.23 | 176 |
| PY2023 | Principal investigator | $567,440.91 | 133 |
| PY2022 | Principal investigator | $365,491.23 | 120 |
| PY2021 | Principal investigator | $860,147.20 | 295 |
| PY2020 | Recipient | $2,524.60 | 1 |
| PY2020 | Principal investigator | $1,161,353.77 | 160 |
| PY2019 | Recipient | $6,753.02 | 2 |
| PY2019 | Principal investigator | $926,535.54 | 156 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
97 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Incyte Corporation | $1,500.00 | 12/19/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240572164 |
| Principal investigator 1 | Incyte Corporation | $1,000.00 | 12/19/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240572170 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $484.78 | 12/09/2025 | Non-covered Recipient Entity OPTIMED RESEARCH | IS744CS7 | No dispute reported | 06/30/2026 | 1246791197 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $1,693.91 | 12/09/2025 | Non-covered Recipient Entity OPTIMED RESEARCH | IS744CS7 | No dispute reported | 06/30/2026 | 1246791200 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $11,665.80 | 11/25/2025 | Non-covered Recipient Entity MULTIPLE DOCTORS | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192186165 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,837.80 | 11/25/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) | No dispute reported | 06/30/2026 | 1223288753 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $19,630.00 | 11/21/2025 | Non-covered Recipient Entity Optimed Research, Limited | A Phase 3, Multi-Center, Multi-National, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Active Eosinophilic Esophagitis. | No dispute reported | 06/30/2026 | 1235994854 |
| Principal investigator 1 | ABBVIE INC. | $10,154.70 | 11/18/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202524489 |
| Principal investigator 1 | ABBVIE INC. | $10,154.70 | 11/18/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202524491 |
| Principal investigator 1 | ABBVIE INC. | $1,418.50 | 11/05/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | No dispute reported | 06/30/2026 | 1202521329 |
| Principal investigator 1 | ABBVIE INC. | $12,931.39 | 11/05/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202521331 |
| Principal investigator 1 | ABBVIE INC. | $9,672.40 | 11/05/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 | No dispute reported | 06/30/2026 | 1202521333 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $484.78 | 10/14/2025 | Non-covered Recipient Entity OPTIMED RESEARCH | IS744CS7 | No dispute reported | 06/30/2026 | 1246789290 |
| Principal investigator 1 | ABBVIE INC. | $1,051.90 | 10/10/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | No dispute reported | 06/30/2026 | 1202516563 |
| Principal investigator 1 | ABBVIE INC. | $1,830.60 | 10/10/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease | No dispute reported | 06/30/2026 | 1202516565 |
| Principal investigator 1 | ABBVIE INC. | $8,818.60 | 10/10/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 | No dispute reported | 06/30/2026 | 1202516567 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $10,189.78 | 09/25/2025 | Non-covered Recipient Entity OPTIMED RESEARCH | A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista | No dispute reported | 06/30/2026 | 1190298503 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $1,965.23 | 09/15/2025 | Non-covered Recipient Entity OPTIMED RESEARCH | IS744CS7 | No dispute reported | 06/30/2026 | 1246787383 |
| Principal investigator 1 | Incyte Corporation | $1,000.00 | 09/05/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240572158 |
| Principal investigator 1 | ABBVIE INC. | $1,179.30 | 09/04/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease | No dispute reported | 06/30/2026 | 1202509254 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $6,840.00 | 09/03/2025 | Non-covered Recipient Entity MULTIPLE DOCTORS | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192152473 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $2,777.75 | 08/13/2025 | Non-covered Recipient Entity OPTIMED RESEARCH | A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS | No dispute reported | 06/30/2026 | 1185554632 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,931.10 | 08/13/2025 | Non-covered Recipient Entity MULTIPLE DOCTORS | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192152469 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $1,747.80 | 08/07/2025 | Non-covered Recipient Entity OPTIMED RESEARCH | IS744CS7 | No dispute reported | 06/30/2026 | 1246786326 |
| Principal investigator 1 | ABBVIE INC. | $419.50 | 08/06/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 | No dispute reported | 06/30/2026 | 1202502671 |
| Principal investigator 1 | ABBVIE INC. | $5,556.00 | 08/06/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | No dispute reported | 06/30/2026 | 1202502791 |
| Principal investigator 1 | ABBVIE INC. | $1,189.25 | 08/06/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 | No dispute reported | 06/30/2026 | 1202502793 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,875.00 | 08/06/2025 | Non-covered Recipient Entity MULTIPLE DOCTORS | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192186160 |
| Principal investigator 1 | ABBVIE INC. | $240.00 | 07/31/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | No dispute reported | 06/30/2026 | 1202500690 |
| Principal investigator 1 | ABBVIE INC. | $10,154.70 | 07/25/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202499762 |
| Principal investigator 1 | ABBVIE INC. | $10,154.70 | 07/25/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202499764 |
| Principal investigator 1 | ABBVIE INC. | $10,154.70 | 07/25/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202499766 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $8,428.00 | 07/23/2025 | Non-covered Recipient Entity MULTIPLE DOCTORS | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192186157 |
| Principal investigator 1 | ABBVIE INC. | $80.00 | 07/18/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 | No dispute reported | 06/30/2026 | 1202498916 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $3,441.70 | 07/14/2025 | Non-covered Recipient Entity OPTIMED RESEARCH | IS744CS7 | No dispute reported | 06/30/2026 | 1246785255 |
| Principal investigator 1 | ABBVIE INC. | $1,189.25 | 07/03/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 | No dispute reported | 06/30/2026 | 1202496785 |
| Principal investigator 1 | ABBVIE INC. | $4,800.00 | 07/03/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 | No dispute reported | 06/30/2026 | 1202496787 |
| Principal investigator 1 | ABBVIE INC. | $5,556.00 | 07/03/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | No dispute reported | 06/30/2026 | 1202496801 |
| Principal investigator 1 | ABBVIE INC. | $2,904.66 | 07/03/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202496803 |
| Principal investigator 1 | ABBVIE INC. | $6,000.00 | 07/03/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 | No dispute reported | 06/30/2026 | 1202496805 |
| Principal investigator 1 | ABBVIE INC. | $1,179.30 | 07/03/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease | No dispute reported | 06/30/2026 | 1202496809 |
| Principal investigator 1 | ABBVIE INC. | $600.00 | 07/03/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | No dispute reported | 06/30/2026 | 1202496811 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $250.50 | 07/01/2025 | Non-covered Recipient Entity OPTIMED RESEARCH | A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista | No dispute reported | 06/30/2026 | 1190306985 |
| Principal investigator 1 | ABBVIE INC. | $1,444.40 | 06/04/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 | No dispute reported | 06/30/2026 | 1202490085 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $135.00 | 06/01/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF NORTH CAROLINA HOSP. | A Phase 3 Single Arm Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (TAK-881) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | No dispute reported | 06/30/2026 | 1223272599 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,312.00 | 06/01/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF NORTH CAROLINA HOSP. | A Phase 3 Single Arm Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (TAK-881) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | No dispute reported | 06/30/2026 | 1223272601 |
| Principal investigator 1 | ABBVIE INC. | $2,904.66 | 05/08/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202484241 |
| Principal investigator 1 | ABBVIE INC. | $2,470.40 | 05/07/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | No dispute reported | 06/30/2026 | 1202482509 |
| Principal investigator 1 | ABBVIE INC. | $8,013.90 | 05/07/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease | No dispute reported | 06/30/2026 | 1202482513 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $646.20 | 04/23/2025 | Non-covered Recipient Entity MULTIPLE DOCTORS | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192186169 |
| Principal investigator 1 | ABBVIE INC. | $2,052.30 | 04/04/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | No dispute reported | 06/30/2026 | 1202474407 |
| Principal investigator 1 | ABBVIE INC. | $1,444.40 | 04/04/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 | No dispute reported | 06/30/2026 | 1202474415 |
| Principal investigator 1 | Incyte Corporation | $123.90 | 04/02/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240572131 |
| Principal investigator 1 | Incyte Corporation | $9.60 | 04/02/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240572136 |
| Principal investigator 1 | Incyte Corporation | $49.56 | 04/02/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240572144 |
| Principal investigator 1 | Incyte Corporation | $35.52 | 04/02/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240572150 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $175.00 | 03/24/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) | No dispute reported | 06/30/2026 | 1223276965 |
| Principal investigator 1 | ABBVIE INC. | $10,154.70 | 03/20/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | M23-784 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202465191 |
| Principal investigator 1 | ABBVIE INC. | $10,154.70 | 03/20/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | M23-784 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202465195 |
| Principal investigator 1 | ABBVIE INC. | $2,904.66 | 03/10/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | M23-784 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202462208 |
| Principal investigator 1 | ABBVIE INC. | $5,037.80 | 03/07/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | M14-533 - A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | No dispute reported | 06/30/2026 | 1202461032 |
| Principal investigator 1 | ABBVIE INC. | $4,189.20 | 03/07/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | M16-000 - A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease | No dispute reported | 06/30/2026 | 1202461036 |
| Principal investigator 1 | ABBVIE INC. | $1,189.25 | 03/07/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | M14-430 - A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 | No dispute reported | 06/30/2026 | 1202461349 |
| Principal investigator 1 | Celgene Corporation | $9,202.00 | 03/07/2025 | Non-covered Recipient Entity Optimed Research | A Phase 1, open-label, single-sequence study to evaluate potential disease-mediated drug-drug interaction with selected cytochrome P450 substrates in adult subjects with active eosinophilic esophagitis receiving cendakimab | No dispute reported | 06/30/2026 | 1222306617 |
| Principal investigator 1 | Incyte Corporation | $1.96 | 03/03/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240572050 |
| Principal investigator 1 | Incyte Corporation | $24.68 | 03/03/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240572057 |
| Principal investigator 1 | Incyte Corporation | $8.82 | 03/03/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240572063 |
| Principal investigator 1 | Incyte Corporation | $49.36 | 03/03/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240572068 |
| Principal investigator 1 | Incyte Corporation | $32.36 | 03/03/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240572075 |
| Principal investigator 1 | Incyte Corporation | $45.80 | 03/03/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240572080 |
| Principal investigator 1 | Incyte Corporation | $22.89 | 03/03/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240572092 |
| Principal investigator 1 | Incyte Corporation | $22.89 | 03/03/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240572099 |
| Principal investigator 1 | Incyte Corporation | $22.89 | 03/03/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240572103 |
| Principal investigator 1 | Incyte Corporation | $22.89 | 03/03/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240572109 |
| Principal investigator 1 | Incyte Corporation | $173.55 | 03/03/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240572114 |
| Principal investigator 1 | Incyte Corporation | $2,388.00 | 02/19/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240572033 |
| Principal investigator 1 | ABBVIE INC. | $736.00 | 02/14/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | M23-784 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202451914 |
| Principal investigator 1 | ABBVIE INC. | $3,188.00 | 02/06/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | M14-533 - A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | No dispute reported | 06/30/2026 | 1202447460 |
| Principal investigator 1 | ABBVIE INC. | $1,189.25 | 02/06/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | M14-430 - A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 | No dispute reported | 06/30/2026 | 1202447542 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,765.70 | 02/03/2025 | Non-covered Recipient Entity MULTIPLE DOCTORS | A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | No dispute reported | 06/30/2026 | 1192152464 |
| Principal investigator 1 | Incyte Corporation | $1,655.00 | 01/17/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240572017 |
| Principal investigator 1 | Incyte Corporation | $1,860.00 | 01/17/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240572027 |
| Principal investigator 1 | Celgene Corporation | $39,065.00 | 01/13/2025 | Non-covered Recipient Entity Optimed Research | A Phase 3, Multi-Center, Multi-National, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Active Eosinophilic Esophagitis. | No dispute reported | 06/30/2026 | 1222306625 |
| Principal investigator 1 | ABBVIE INC. | $2,193.30 | 01/03/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | M16-000 - A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease | No dispute reported | 06/30/2026 | 1202436385 |
| Principal investigator 1 | ABBVIE INC. | $2,228.60 | 01/03/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | M14-533 - A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | No dispute reported | 06/30/2026 | 1202436390 |
| Principal investigator 1 | ABBVIE INC. | $489.70 | 01/03/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | M14-430 - A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 | No dispute reported | 06/30/2026 | 1202436393 |
| Principal investigator 1 | Incyte Corporation | $30.52 | 01/02/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240571996 |
| Principal investigator 1 | Incyte Corporation | $7.84 | 01/02/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240572001 |
| Principal investigator 1 | Incyte Corporation | $3.84 | 01/02/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240572007 |
| Principal investigator 1 | Incyte Corporation | $19.20 | 01/02/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240572011 |
| Principal investigator 1 | Incyte Corporation | $22.08 | 01/02/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240572023 |
| Principal investigator 1 | Incyte Corporation | $99.12 | 01/02/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240572039 |
| Principal investigator 1 | Incyte Corporation | $30.52 | 01/02/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240572045 |
| Principal investigator 1 | Incyte Corporation | $74.34 | 01/02/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240572086 |
| Principal investigator 1 | Incyte Corporation | $30.52 | 01/02/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240572119 |
| Principal investigator 1 | Incyte Corporation | $30.52 | 01/02/2025 | Non-covered Recipient Entity OPTIMED RESEARCH LTD | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 1240572125 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $6,503.75 | 01/01/2025 | Non-covered Recipient Entity OPTIMED RESEARCH | A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Chronic Spontaneous U | No dispute reported | 06/30/2026 | 1190306981 |
Ownership and Investment Interests
One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together
| Program year | Measure | Amount | Records |
|---|---|---|---|
| PY2024 | Amount invested | $2,000.00 | 1 |
| PY2024 | Value of interest | $2,000.00 | 1 |
Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.
Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.
Ownership and Investment Interests records
Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them
1 record · PY2024
| Program year | Company | Amount invested | Value of interest | Terms of interest | Interest held by | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| PY2024 | Consortium of Independent Immunology Clinics, LLC | $2,000.00 | $2,000.00 | n/a | Physician Covered Recipient | No dispute reported | 06/30/2026 | 1147108215 |